Xyosted ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 13 | 多発性硬化症／視神経脊髄炎 | 1 |
13. 多発性硬化症／視神経脊髄炎
臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04601233 (ClinicalTrials.gov) | December 2021 | 2/10/2020 | Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis | Testosterone TReatment for Erectile Dysfunction in Male Multiple Sclerosis Patients With Low Testosterone (TTRED-MS Study) | Multiple Sclerosis;Erectile Dysfunction;Testosterone Deficiency | Drug: XYOSTED 75 milligram (mg) in 0.5 ML Auto-Injector | Tulane University | Louisiana State University Health Sciences Center in New Orleans;Antares Pharma Inc. | Not yet recruiting | 18 Years | N/A | Male | 20 | Phase 4 | United States |